The studies behind each numbered fact
BPC-157 References You Can Check
Researchers first made the compound to study hurt tissue. You can check each number against a study, review, or FDA page below.
A bracketed number leads to the full source
A research team made BPC-157 from a stomach protein. These sources back the facts on each page. A mark such as [N] points to that source below. The research, tissue, amount, law, and FAQ pages use them. Most papers link to PubMed, a public medical paper list. A DOI is a paper's permanent lookup link. FDA facts link to FDA pages.
The list holds old and new work. It starts with the 2003 cut-tendon study [1]. Next comes the 2004 stomach-sore test [4]. A 2017 paper covers new blood vessels [3]. The 2022 paper tracked how animals got rid of the compound [2]. Three small human tests also appear [6][10][14]. Reviews and rat work from 2024-2026 follow [8][9][11][12][13][15]. Two FDA pages support the law facts [16][17].
Most papers here cover animals, not people. Much early work came from one research team [11]. Other teams still need to repeat the findings. The three human tests show you how thin that work is. You can check each numbered claim below. When no test exists, we say so without a number.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
- Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
- Sikiric P, et al. Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157. Biomedicines. 2021;9(11):1506. ↗
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Effect Following Intoxications. Pharmaceuticals (Basel). 2025;18(6):928. ↗
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
- Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
- Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act; and July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (public agenda listing BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List). Verified 2026-05-29. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 (free base) and BPC-157 acetate: nominations withdrawn after earlier Category 2 placement; FDA still records safety concerns). Verified 2026-05-29. ↗
- Author group (2025) BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025. 18:1450. ↗
- Tohyama Y, et al. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004. 76:345-357. ↗
- Boban Blagaic A, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005. 512:173-179. ↗
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. 19:19066-19077. ↗